- Home
- EIC vs LXEO Comparison
EIC vs LXEO Comparison
Compare EIC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- LXEO
- Stock Information
- Founded
- EIC N/A
- LXEO 2017
- Country
- EIC United States
- LXEO United States
- Employees
- EIC N/A
- LXEO 72
- Industry
- EIC Finance/Investors Services
- LXEO
- Sector
- EIC Finance
- LXEO
- Exchange
- EIC Nasdaq
- LXEO Nasdaq
- Market Cap
- EIC 287.1M
- LXEO 190.9M
- IPO Year
- EIC 2019
- LXEO 2023
- Fundamental
- Price
- EIC $16.02
- LXEO $5.95
- Analyst Decision
- EIC
- LXEO Strong Buy
- Analyst Count
- EIC 0
- LXEO 5
- Target Price
- EIC N/A
- LXEO $23.80
- AVG Volume (30 Days)
- EIC 116.0K
- LXEO 219.1K
- Earning Date
- EIC 11-14-2023
- LXEO 02-11-2025
- Dividend Yield
- EIC 13.63%
- LXEO N/A
- EPS Growth
- EIC N/A
- LXEO N/A
- EPS
- EIC 0.80
- LXEO N/A
- Revenue
- EIC N/A
- LXEO N/A
- Revenue This Year
- EIC N/A
- LXEO N/A
- Revenue Next Year
- EIC N/A
- LXEO N/A
- P/E Ratio
- EIC $20.31
- LXEO N/A
- Revenue Growth
- EIC N/A
- LXEO N/A
- 52 Week Low
- EIC $13.00
- LXEO $4.67
- 52 Week High
- EIC $16.48
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- EIC 65.93
- LXEO 43.99
- Support Level
- EIC $15.71
- LXEO $5.18
- Resistance Level
- EIC $15.75
- LXEO $5.60
- Average True Range (ATR)
- EIC 0.11
- LXEO 0.54
- MACD
- EIC 0.03
- LXEO 0.04
- Stochastic Oscillator
- EIC 100.00
- LXEO 51.01
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.